Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director · Chief Executive Officer | March 11, 2025 | March 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date March 11, 2025 · Filed March 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2035-03-11 | Direct | 2,925,098 |
Reported balance
After 2025-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-11 · Grant · Acquired 758,400 · Balance 2,925,098 F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 13, 2025 16:02 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 758,400 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000950170-25-038694 · ownership.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,925,098 Underlying: Common Stock · 758,400 shares Expires 2035-03-11 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 18:39 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 510,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001628280-24-009745 · wk-form4_1709854769.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,170,310 Underlying: Common Stock · 510,000 shares Expires 2034-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 17:41 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 482,064 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001628280-23-008354 · wf-form4_167900288656705.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,664,477 Underlying: Common Stock · 482,064 shares Expires 2033-03-15 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 16:11 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 10,000 | $1.43 | $14,300.00 |
DisclosureSEC source: 0001628280-22-030946 · wf-form4_166975625707899.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,481 Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 18:39 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 370,128 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005790 · wf-form4_164695553669989.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,185,400 Underlying: Common Stock · 370,128 shares Expires 2032-03-09 F1 · derivative.exercise_date: 92,532 vest on 3/09/2023. 7,711 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 16:11 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 435,072 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012172 · wf-form4_162370149350115.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,272 Underlying: Common Stock · 435,072 shares Expires 2031-06-10 F1 · derivative.exercise_date: 108,768 vest on 6/10/2022. 9,064 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025. Read SEC document |
| March 23, 2021 Filed Mar 23, 2021 12:24 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 965 | $10.34 | $9,979.74 |
DisclosureSEC source: 0001628280-21-005335 · wf-form4_161651662768276.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,481 Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 16:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 260 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000060 · wf-form4_160988059527289.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock. F4 · derivative.exercise_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 16:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | Tax withholdingCommon Stock | 113 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000060 · wf-form4_160988059527289.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,516 F2 · shares: The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021. Read SEC document |
| January 02, 2021 Filed Jan 5, 2021 16:03 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | Exercise / conversionCommon Stock | 260 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000060 · wf-form4_160988059527289.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:15 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 221,241 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075234 · a4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,200 Underlying: Common Stock · 221,241 shares Expires 2030-06-17 F1 · derivative.exercise_date: 73,747 vest on each of 6/17/2021, 2022 and 2023. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:17 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 6,993 | $1.43 | $9,999.99 |
DisclosureSEC source: 0001104659-20-063184 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,369 Read SEC document |
| January 03, 2020 Filed Jan 3, 2020 16:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 116 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 116 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2020. Read SEC document |
| January 03, 2020 Filed Jan 3, 2020 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 552 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 552 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January l, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 261 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260 Underlying: Common Stock · 261 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 261 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000881 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000872 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,533 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 466 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October l, 2019. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 16:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052973 · a4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 461 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,749 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 461 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on July l, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 06:21 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-019005 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 16:06 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 134,203 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017920 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,959 Underlying: Common Stock · 134,203 shares Expires 2029-06-20 F1 · derivative.exercise_date: 44,734 vest on each of 6/20/2020 and 2021 and 44,735 vest on 6/20/2022 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,271 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 459 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009746 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,125 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 698 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,010 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 698 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:10 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000518 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,688 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 3,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,145 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 3,035 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 1, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 16:05 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000506 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,188 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 2,731 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,680 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 2,731 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October 1, 2018. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 17:09 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-026063 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 16:30 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020661 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,688 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: 7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. F2 · derivative.expiration_date: 7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 90,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 42,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,367 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 42,930 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 30, 2018. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on April 10, 2017. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 17:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 672,189 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001904 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,782,189 Underlying: Common Stock · 672,189 shares Expires 2028-01-23 F1 · derivative.exercise_date: 522,189 vest immediately upon grant and 50,000 vest on each of 1/23/2019, 2020 and 2021. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 9,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,297 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 9,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,243 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| September 02, 2017 Filed Sep 6, 2017 20:41 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 30,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055891 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 30,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. Read SEC document |
| September 02, 2017 Filed Sep 6, 2017 20:41 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Tax withholdingCommon Stock | 12,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055891 · a4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,051 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 12,928 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on September 2, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.